Home > Boards > US Listed > Medical - Drugs > Versartis, Inc. (VSAR)

There were a few things the markets didn't

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Lone Wolf Member Profile
 
Followed By 980
Posts 30,790
Boards Moderated 5
Alias Born 07/13/10
160x600 placeholder
Lone Wolf   Saturday, 09/23/17 06:30:25 PM
Re: Marilynt post# 169
Post # of 814 
There were a few things the markets didn't seem to care about / factor in Friday. Trading was all about downside momentum.

Here are the issues that should be factored in going forward...and explains the multiple unchanged ratings from the financial institutions:

1- cash on hand = a PPS of $4
2- A major Japanese Pharma had given them a 40mil upfront payment and has milestone payments in place for the future.
3- company can be approved for the drugs abroad...Japan likely first in line.

Perhaps the most important is the following...company's drug IS successful. The phase III results released Friday compared the daily dosage results of Pfizer's drug to VSAR's bi-monthly drug! That's crazy!! It's like comparing apples to oranges.

Okay...that said...company should come out on Monday and emphasize that they still plan on submitting this for approval...again...it's a proven successful drug with no difference in side effects.

Lastly...I won't say who, what, where or how I know...ill just say the markets should 'drill down' and give some thought to what the response has been from parents whose children were involved in the clinical trials...if they do, they will see it speaks volumes about what the parents of the children receiving the drug feel about it and its effectiveness compared to the daily dosage drug.

Watch this end up being a take-over candidate if current prices remain what they are.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist